IMEXHS Wins 20-Hospital Mexico Contract to Add $384K in Recurring Revenue
IMEXHS secures 20-site Mexico hospital contract, adding $384,000 in ARR
IMEXHS Limited (ASX: IME) has won a public tender to deploy its Aquila+ platform across 20 hospitals and clinics in Zacatecas, Mexico, adding $384,000 in new Annual Recurring Revenue (ARR) plus a one-time implementation fee of $50,000. The contract was secured through distributor partner GOBA and marks a meaningful step in the company’s Mexico expansion strategy.
When big ASX news breaks, our subscribers know first
Inside the deployment — AI workflow agents and diagnostic algorithms at scale
Five proprietary AI agents plus two Gleamer algorithms across all 20 sites
The Zacatecas deployment spans all 20 public hospital sites and integrates multiple layers of AI capability into the Aquila+ platform. According to the company’s own characterisation, the combination of agentic workflow automation and embedded diagnostic AI across a public hospital network represents “one of the most comprehensive AI-integrated radiology deployments undertaken anywhere to date.”
The key components of the deployment are:
- Platform: Aquila+
- Sites: 20 public hospitals and clinics, Zacatecas, Mexico
- AI workflow layer: Five proprietary AI workflow agents embedded across Aquila+
- Diagnostic AI: Gleamer’s ChestView and Fracture Detection algorithms
- Distribution partner: GOBA
Timeline and ARR run rate
Implementation has commenced, with completion across all 20 sites targeted by the end of June 2026. The full ARR run rate is expected from September 2026, reflecting a two-stage path from implementation to revenue contribution that investors should track closely.
| Metric | Detail |
|---|---|
| New ARR | $384,000 |
| Implementation fee | $50,000 (one-time) |
| Sites | 20 public hospitals and clinics |
| Implementation completion | End of June 2026 |
| Full ARR run rate from | September 2026 |
What is Aquila+ and why AI-integrated radiology matters for public hospitals
Aquila+ is a cloud-based, vendor-neutral radiology platform that combines Picture Archiving and Communications System (PACS) and Radiology Information System (RIS) functionality. PACS handles the storage and retrieval of medical images, while RIS manages the associated patient and workflow data. Critically, the platform requires no installed software, meaning hospitals can access it entirely through the cloud with minimal infrastructure requirements.
The five proprietary AI workflow agents embedded within Aquila+ are designed to automate repetitive steps in the radiology workflow, such as routing images, prioritising cases, and managing reporting queues. This reduces manual workload, lowers the potential for human error, and allows radiology staff to focus on higher-value diagnostic tasks.
Gleamer’s ChestView and Fracture Detection algorithms add a diagnostic AI layer. ChestView assists radiologists in identifying chest pathology from imaging data, while Fracture Detection supports the identification of bone fractures. Both tools are designed to support, not replace, clinical decision-making.
For a public hospital system, this combination addresses a genuine operational challenge. Public health networks typically manage high patient volumes with constrained staffing and budgets. Scalable, cloud-deployed AI tools offer a practical means of improving diagnostic throughput without proportional cost increases.
From an investor perspective, the structure is straightforward. The SaaS-based ARR model means the $384,000 in annual revenue is recurring and predictable once all 20 sites are fully operational, providing a visible baseline contribution to IMEXHS’s total ARR.
The next major ASX story will hit our subscribers first
Mexico expansion strategy and what this contract signals
This contract win is consistent with IMEXHS’s stated Mexico expansion strategy and demonstrates the company’s ability to compete successfully in public sector procurement processes, which are often more complex and competitive than private sector arrangements.
IMEXHS currently operates across 18 countries, and Mexico represents an active growth market within that footprint. The Zacatecas win is not an isolated opportunity; it reflects a deliberate effort to build presence in the Mexican public health system through structured tender participation.
The role of distributor partner GOBA is also worth noting. The contract was secured through GOBA’s local channel relationships, indicating that IMEXHS’s distribution model is generating tangible outcomes in-market. For companies expanding into Latin American public health systems, having an established local distribution partner with the capacity to navigate procurement processes is a material operational advantage.
Looking ahead, the full ARR run rate of $384,000 is expected from September 2026, following the completion of all 20 site implementations by the end of June 2026. The contract adds to IMEXHS’s recurring revenue base and reinforces the company’s positioning as a competitive participant in public-sector radiology infrastructure across its target markets.
Don’t Miss the Next Healthcare Breakout on the ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already staying ahead of the market. Click the “Free Alerts” button at StockWire X to get the next market-moving announcement the moment it drops.